Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$4.45 USD
+0.11 (2.53%)
Updated May 17, 2024 03:41 PM ET
After-Market: $4.42 -0.03 (-0.67%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CELZ 4.45 +0.11(2.53%)
Will CELZ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CELZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELZ
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
CELZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Creative Medical (CELZ) Up 82% on Stem Cell Treatment Data
Other News for CELZ
CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024
Creative Medical Technology Holdings Provides Corporate Update
BREA, MSAI and APM among pre-market losers
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?